Published On: Thu, Feb 26th, 2015

RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage

RegeneRx was recently allowed by the FDA to move into Phase III clinical trials with RGN-259 for the treatment of patients with NK.

RegeneRx

RegeneRx Biopharmaceuticals, Inc, an American publicly traded, clinical-stage, biopharmaceutical company, has received an Israeli patent with claims for preventing, inhibiting or reducing heart tissue deterioration, injury or damage, and for restoring heart tissue. The patent includes claims using thymosin beta 4, various fragments and analogues. It will expire in July 2026.

RegeneRx acquired the rights to a novel peptide from the NIH in 1999. This intellectual property for Thymosin Beta 4 (Tβ4) allowed the company to direct its focus on tissue protection and repair in multiple disease indications.

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the U.S., and has an extensive worldwide patent portfolio covering its products. RGN-259, the Company’s ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a primary focus of RegeneRx’s clinical development efforts in the U.S.

RegeneRx was recently allowed by the FDA to move into Phase III clinical trials with RGN-259 for the treatment of patients with NK. The Company’s partners are in various stages of development of RGN-259 for dry eye syndrome in their respective territories.

Read more about: , , , , , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems